Back to results
US 2009/0275633 A1Published application
Novel Tumour Suppressor
AssigneeOncomethylome Sciences SA
InventorManel Esteller
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOncomethylome Sciences SA
InventorManel Esteller
Estimating the term…
A method of diagnosing cancer includes the steps of, in a sample obtained from a subject, determining the level or activity of HDAC2. A reduced level or activity of HDAC2 is indicative of cancer. HDAC2 protein expression is preferably determined. Indirect determination of HDAC2 expression is also possible, preferably by looking at the expression of genes selected from NCOA4, CTSB, TBCD, PPP2R4 and CORO1C. Methods for predicting the probability of successful treatment of cancer using a hydroxamic acid based HDAC inhibitor and for selecting suitable cancer treatment regimens can also be based upon determining the level or activity of HDAC2. Methods of treatment of cancer may be based upon use of carboxylic acid based HDAC inhibitors or by reconstituting HDAC2 activity.
A method of diagnosing cancer comprising, in a sample obtained from a subject, determining the level or activity of HDAC2, wherein a reduced level or activity of HDAC2 is indicative of cancer.
A method for predicting the probability of successful treatment of cancer with a hydroxamic acid based HDAC inhibitor comprising, in a sample obtained from a subject, determining the level or activity of HDAC2, wherein a reduced level or activity of HDAC2 is indicative of a low probability of successful treatment with the hydroxamic acid based HDAC inhibitor.
A method of selecting a suitable treatment regimen for cancer comprising, in a sample obtained from a subject, determining the level or activity of HDAC2, wherein a reduced level or activity of HDAC2 indicates that treatment using a hydroxamic acid based HDAC inhibitor is unsuitable.
A method of selecting a suitable treatment regimen for cancer comprising, in a sample obtained from a subject, determining the level or activity of HDAC2, wherein a reduced level or activity of HDAC2 indicates that treatment using a carboxylic acid based HDAC inhibitor should be selected.
(canceled)
A method for treating cancer in a subject, said subject having a reduced level or activity of HDAC2, comprising reconstitution of HDAC2 activity in the subject.
Dependencies are inferred from the claim text.